Filing Flows › Theravance Biopharma (TBPH) › R&D spending
Theravance Biopharma (TBPH) R&D spending by quarter
Theravance Biopharma's R&D spending was $4.7M in Q2 2026 (second quarter 2026), -19% from Q1 2026. Over the last 7 quarters it ranged from $4.7M (Q2 2026) to $11.5M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.7M | -19% | -55% |
| Q1 2026 | $5.8M | -21% | -49% |
| Q4 2025 | $7.4M | -9% | -22% |
| Q3 2025 | $8.1M | -23% | — |
| Q2 2025 | $10.5M | -8% | — |
| Q1 2025 | $11.5M | +21% | — |
| Q4 2024 | $9.5M | — | — |
Q2 2026 at a glance
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Theravance Biopharma's R&D spending?
Theravance Biopharma's R&D spending was $4.7M in Q2 2026 (second quarter 2026), -19% from Q1 2026.
How has Theravance Biopharma's R&D spending changed?
Over the last 7 quarters it ranged from $4.7M (Q2 2026) to $11.5M (Q1 2025).